Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

Biotechguy21 Jun. 30 at 1:47 PM

$AGEN $INKT $PTIX Tale a look at the long term charts. End of story. All these stocks are terrible and love to dilutes SHs to almost zero

1 · Reply

Biotechguy21 Jun. 16 at 8:38 PM

$AGEN $PTIX and don’t forget the other pos $INKT which is down 93% all time. Now look deeper into these and the stories are really interesting 👀👀😂😂🤡🤡

0 · Reply

Biotechguy21 Jun. 12 at 3:46 PM

$AGEN $PTIX $INKT what a great list of stocks 😂😂😂😂😂

0 · Reply

Biotechguy21 Jun. 8 at 10:40 PM

$PTIX $AGEN $INKT look deep into these pos stocks. easiest money ever. 🤡🤡😂😂

0 · Reply

Biotechguy21 Jun. 4 at 11:39 PM

$AGEN congrats on this it’s only down 96.5% all the time. Same ceo. Same board. Same pos stock. Just like $INKT. What will be the excuse this time? 🤡🤡🤡😂😂😂

0 · Reply

Slapshot22 Jun. 4 at 7:26 PM

$INKT MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients Nice to pull some non-dilutive funding. Sort of recognizes the work being done. Good quote: “This non-dilutive funding from NIAID underscores the growing recognition of iNKT cells as a unique and powerful modality in immune regulation,” said Jennifer Buell, PhD, President and Chief Executive Officer of MiNK Therapeutics. "This award both validates the promise of our iNKT platform and accelerates its development in a high-priority area of unmet medical need." Figured someone should post this. https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-awarded-prestigious-niaid-grant-advance-allo

0 · Reply

weichsel1 Jun. 4 at 3:02 AM

$AGEN With a market cap of 150m, and 90m cash on hand from the transaction on June 3rd ( which is at least 18 months of cash burn), the value of the Agenus drugs is only a net 60m. Presuming 30m shares outstanding and 5 dollar a share. Still rather undervalued, and this does not count the value of the interest in $INKT ( majority owned by Agenus).

0 · Reply

Biotechguy21 May. 21 at 12:42 AM

$AGEN $INKT two worthless stocks. same team = same failures

1 · Reply

2_logs_higher May. 16 at 12:50 PM

$AGEN & $INKT Amazing the PR dept does not work for Mink either. MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2025 financial results and clinical progress. The company achieved a significant breakthrough with a complete remission in testicular cancer using a single infusion of agenT-797. Clinical trials are advancing, including an active Phase 2 trial in gastric cancer at Memorial Sloan Kettering. The company presented promising data showing agenT-797's effectiveness in PD-1-resistant gastroesophageal cancers. MiNK is pursuing strategic partnerships in oncology, immunology, and engineered cell therapies. Financially, Q1 2025 ended with $3.2 million cash, reduced cash burn to $1.3 million (vs $2.5M in Q1 2024), and a net loss of $2.8 million ($0.70 per share). The company expects NIAID funding for its GvHD program by June 2025. https://www.stocktitan.net/news/INKT/

1 · Reply

Biotechguy21 May. 6 at 9:38 AM

$AGEN $PTIX $INKT pos stocks. Look into them and do some research. 👀👀🤡🤡

0 · Reply

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 4 weeks ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 1:21 PM EDT - 7 weeks ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 7 weeks ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

May 5, 2025, 12:30 PM EDT - 2 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Mar 18, 2025, 11:28 AM EDT - 3 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 4 months ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 4 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 5 months ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 5 months ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 7 months ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 8 months ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 8 months ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 8 months ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 8 months ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 9 months ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 9 months ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 10 months ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 11 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 11 months ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 1 year ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 1 year ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 1 year ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 1 year ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 1 year ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 1 year ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 1 year ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Sep 27, 2023, 9:05 AM EDT - 1 year ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Aug 24, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in September Investor Conferences

Aug 10, 2023, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Reports Second Quarter 2023 Results

Jul 28, 2023, 8:30 AM EDT - 2 years ago

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

May 22, 2023, 8:30 AM EDT - 2 years ago

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

May 18, 2023, 8:30 AM EDT - 2 years ago

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

May 14, 2023, 2:25 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript

May 11, 2023, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

Apr 27, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

Apr 18, 2023, 1:32 PM EDT - 2 years ago

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

Mar 25, 2023, 2:17 AM EDT - 2 years ago

MiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Up

Mar 21, 2023, 12:26 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript

Biotechguy21 Jun. 30 at 1:47 PM

$AGEN $INKT $PTIX Tale a look at the long term charts. End of story. All these stocks are terrible and love to dilutes SHs to almost zero

1 · Reply

Biotechguy21 Jun. 16 at 8:38 PM

$AGEN $PTIX and don’t forget the other pos $INKT which is down 93% all time. Now look deeper into these and the stories are really interesting 👀👀😂😂🤡🤡

0 · Reply

Biotechguy21 Jun. 12 at 3:46 PM

$AGEN $PTIX $INKT what a great list of stocks 😂😂😂😂😂

0 · Reply

Biotechguy21 Jun. 8 at 10:40 PM

$PTIX $AGEN $INKT look deep into these pos stocks. easiest money ever. 🤡🤡😂😂

0 · Reply

Biotechguy21 Jun. 4 at 11:39 PM

$AGEN congrats on this it’s only down 96.5% all the time. Same ceo. Same board. Same pos stock. Just like $INKT. What will be the excuse this time? 🤡🤡🤡😂😂😂

0 · Reply

Slapshot22 Jun. 4 at 7:26 PM

0 · Reply

weichsel1 Jun. 4 at 3:02 AM

0 · Reply

Biotechguy21 May. 21 at 12:42 AM

$AGEN $INKT two worthless stocks. same team = same failures

1 · Reply

2_logs_higher May. 16 at 12:50 PM

1 · Reply

Biotechguy21 May. 6 at 9:38 AM

$AGEN $PTIX $INKT pos stocks. Look into them and do some research. 👀👀🤡🤡

0 · Reply

Biotechguy21 May. 1 at 1:32 PM

$INKT pos stock just like $AGEN 👀👀🤡🤡

0 · Reply

TruthTooPower Apr. 30 at 11:51 AM

$INKT !!! We Are The Bomb Baby!!!

1 · Reply

Biotechguy21 Apr. 29 at 11:01 AM

$PTIX $AGEN $INKT well well what do we have here? Three POS stocks. 👀👀👀👀👀🤡🤡🤡🤡🤡🔥🔥🔥🔥

1 · Reply

Biotechguy21 Apr. 21 at 11:38 AM

$AGEN $PTIX $INKT look at these three and what do you see???? all loser stocks! And look deeper 😂😂🤡🤡😂😂🤡🤡

0 · Reply

Marinshell Apr. 14 at 4:34 PM

$INKT what does Mink have to do with being a guest at tomorrow’s IBRX investor day announcements??? Cannot wait to hear.

0 · Reply

Biotechguy21 Apr. 10 at 12:14 PM

$AGEN $PTIX $INKT why do all three of these stocks suck so bad? 🤡🤡😂😂👀👀

0 · Reply

PhoenixLights Apr. 8 at 6:53 PM

$IBRX $INKT $ONC seems curious to invite Dr. Mark Lanasa, Senior Vice President, Chief Medical Officer, Solid Tumors, BeiGene, and Dr. Jennifer Buell, President & Chief Executive Officer, MiNK Therapeutics, to ImmunityBio's first ever investors relations day. Perhaps that is common in the Biotech world. https://immunitybio.com/immunitybio-to-host-key-opinion-leader-and-investor-meeting-to-provide-updates-on-clinical-programs-and-anktiva-commercial-launch/

2 · Reply

BixbyKnolls Apr. 8 at 5:38 PM

$IBRX What deal are we doing with $INKT - Mink Therapeutics? One of the speakers next week.

1 · Reply

Slapshot22 Apr. 8 at 2:16 AM

$INKT Stock defines under the radar for me. Always amazed, see a % change, then pull up the volume: 4,520 shares today. Yeap, 4.5K shares is what it says. right around $36K if my math works out. I could move the stock price myself with a decent buy or sell order. Someday this stock may get into the light of day, but for now ... lotto ticket sitting on the back burner ... with not enough liquidity to do anything if you wanted. But, someday it may go mainstream. JMHO.

0 · Reply

Biotechguy21 Apr. 3 at 9:51 PM

$AGEN $INKT this pooor guy is still holding and losing every dime on these pos stocks. Terrible investing 🤡🤡🤡🤡🤡

0 · Reply

2_logs_higher Apr. 3 at 5:48 PM

$AGEN + $INKT Another TIGIT trial fails as BeiGene scraps Phase 3 drug good for inkt. https://endpts.com/another-tigit-trial-fails-as-beigene-scraps-phase-3-drug/

2 · Reply

Cs1992 Apr. 2 at 9:00 AM

$INKT 18 dollar soon

0 · Reply

Market Cap	29.25M
Revenue (ttm)	0.00
Net Income (ttm)	-9.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,300
Avg Vol	8,520
Day's Range	N/A - N/A
Shares Out	3.99M
Stochastic %K	18%
Beta	0.19
Analysts	Strong Sell
Price Target	$35.00